BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Aurobindo Pharma Ltd. Share Price

NSE
BSE

NSE : AUROPHARMA

BSE : 524804

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Price Summary

Previous Close ₹1,686.00
Day's Range ₹1,656.60 - ₹1,699.00
Open ₹1,659.40
52 Week Range ₹1,034.85 - ₹1,706.70
Volume 32,693
Market Cap ₹0.10

Stocks Summary

Trade Value ( ₹ in Lacs) 17,864.36
Market Cap (₹ in Mn) 0.10
Dividend Yield(%) 0.24
Price/Earning (TTM) 25.70
TTM EPS (₹) 64.52
P/E Ratio 21.60
Book Value(₹) 2.45
PAT Margin (%) 5.04
Face Value (₹) 1.00
ROCE(%) 12.76
Trade Value ( ₹ in Lacs) 551.20
Market Cap (₹ in Mn) 0.10
Dividend Yield(%) 0.24
Price/Earning (TTM) 25.70
TTM EPS (₹) 64.52
P/E Ratio 21.60
Book Value(₹) 2.45
PAT Margin (%) 5.04
Face Value (₹) 1.00
ROCE(%) 12.76

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 78681.4 109333.0
Expenses N/A N/A
PBT 12068.0 23584.5
Operating profit 0.0 0.0
Net profit 8242.0 17467.9

Shareholding Pattern

Promoters (% Holding)

51.88%

Mutual funds (% Holding)

16.71%

Non-Institution (% Holding)

6.64%

FI/Banks/Insurance (% Holding)

4.99%

Government (% Holding)

0.00%

FII

16.38%

About Aurobindo Pharma Ltd.

Founded 1986
Managing Director K Nityananda Reddy
NSE Symbol AUROPHARMA

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,55,825.66 1,881.10 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 2,47,018.51 9,570.55 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,86,874.73 4,962.75 3,480.60 - 3,480.60
Apollo Hospitals Enterprise Ltd. 1,25,955.36 8,800.00 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,19,664.26 696.00 0.00 - 0.00
Zydus Lifesciences Ltd. 1,15,211.69 1,150.00 835.50 - 835.50
Cipla Ltd. 1,12,773.00 1,383.95 1,165.70 - 1,165.70
Laurus Labs Ltd. 1,00,943.83 1,945.50 823.10 - 823.10
Max Healthcare Institute Ltd. 96,425.85 990.00 903.00 - 903.00
Lupin Ltd. 96,254.46 2,112.00 1,900.00 - 1,900.00
no-content No Records Found

Latest News

Sep
1
2026
EQUITY Posted on Sep 1st 2026

Aurobindo Pharma informs about disclosure

Aurobindo Pharma has informed that, Pharma Private, a wholly owned subsidiary of the Company has incorporated a new wholly owned subsidiary by the name of ‘Avogent Lifesciences’ in India. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure A’.

The above information is a part of company’s filings submitted to BSE.

Read More
Aug
31
2026
EQUITY Posted on Aug 31st 2026

Aurobindo Pharma informs about press release

Aurobindo Pharma has informed that it enclosed a copy of the Press Release that is being issued by the Company in connection with launch of generic version of Advair Diskus® in the US by Lannett Company LLC, wholly owned stepdown subsidiary of the Company.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
17
2026
EQUITY Posted on Aug 17th 2026

Aurobindo Pharma informs about clarification

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: The United States Food and Drug Administration (USFDA) inspected Raleigh Plant, North Carolina, USA, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, established for manufacturing Inhalers, Dermatology and Transdermal products, from March 24, 2025, to April 10, 2025. At the end of inspection, form 483 was issued with a total of 11 observations. The Unit has now received Establishment Inspection Report (EIR), classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). The USFDA has concluded that this inspection is now closed. As this unit is classified as VAI, pending applications for multiple inhalers and other dosage forms filed from this facility can now progress through the USFDA’s review process.
The above information is a part of company’s filings submitted to BSE.  
Read More
Aug
4
2026
EQUITY Posted on Aug 4th 2026

Aurobindo Pharma informs about press release

Aurobindo Pharma has informed that it enclosed copies of the Notice published in the newspapers, Business Standard and Nava Telangana on August 4, 2026, intimating the shareholders about dispatch (through e-mail only) of the Notice of 39th Annual General Meeting of the Company to be held on Thursday, August 27, 2026, at 3:30 pm IST through Video Conferencing (VC) / Other Audio Visual Means(OAVM) and Annual Report for the financial year 2025-26, e-voting information and Book Closure dates.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
EQUITY Posted on Jul 30th 2026

Aurobindo Pharma informs about press release

Aurobindo Pharma has informed that it enclosed copies of the Notice published in the newspapers, Business Standard and Nava Telangana on July 30, 2026, intimating the shareholders that the 39th Annual General Meeting of the Company will be held on Thursday, August 27, 2026, at 3:30 pm (IST) through Video Conferencing / Other Audio-Visual Means.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Aurobindo Pharma Ltd. ?

The current share price of Aurobindo Pharma Ltd. is ₹1,692.00 as of 2026-09-08.

The market capitalisation of Aurobindo Pharma Ltd. is ₹95,397.65 as of 2026-09-07.

The 1-year return of Aurobindo Pharma Ltd. is 647.90% as of 2026-09-08.

The P/E ratio of Aurobindo Pharma Ltd. is 21.60 as of 2026-09-08.

The 52-week high and low of Aurobindo Pharma Ltd. are ₹1,717.00 and ₹1,035.40, respectively, as of 2026-09-08.

The dividend yield of Aurobindo Pharma Ltd. is 0.2413% as of2026-09-07.

You can buy Aurobindo Pharma Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Aurobindo Pharma Ltd. is K Nityananda Reddy.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore